Alteon pimagedine
Executive Summary
Phase III trial of the AGE formation inhibitor in end-stage renal disease has been discontinued. The company said it may use data from the study to support a definitive trial of the drug if Alteon decides to continue to pursue the indication. Alteon is planning to meet this quarter with FDA regarding the already completed pimagedine Phase III ACTION trial in type 1 diabetics with overt nephropathy or progressive kidney disease. The firm reported in November that the trial's primary endpoint of a 50% reduction in the time to retinopathy failed to reach statistical significance, although there were improvements in secondary endpoints. Alteon expects to receive fast track designation for pimagedine if an NDA is filed
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth